search
Back to results

A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions

Primary Purpose

Depression

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Bupropion HCI ER Tablets, 150 mg; EON Labs Inc.
WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline
Sponsored by
Sandoz
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Depression

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

  • Positive test results for HIV or hepatitis B or C.
  • Treatment for drug or alcohol dependence.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    1

    2

    Arm Description

    Bupropion HCI ER Tablets, 150 mg

    WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg

    Outcomes

    Primary Outcome Measures

    Bioequivalence according to US FDA timelines

    Secondary Outcome Measures

    Full Information

    First Posted
    March 13, 2009
    Last Updated
    March 27, 2017
    Sponsor
    Sandoz
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00864981
    Brief Title
    A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions
    Official Title
    A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2009
    Overall Recruitment Status
    Completed
    Study Start Date
    September 2005 (undefined)
    Primary Completion Date
    October 2005 (Actual)
    Study Completion Date
    October 2005 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Sandoz

    4. Oversight

    5. Study Description

    Brief Summary
    The purpose of this study is to demonstrate the relative bioequivalence of Bupropion HCI 150 mg SR Tablets under fasting conditions.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Depression

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Crossover Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    32 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    1
    Arm Type
    Experimental
    Arm Description
    Bupropion HCI ER Tablets, 150 mg
    Arm Title
    2
    Arm Type
    Active Comparator
    Arm Description
    WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg
    Intervention Type
    Drug
    Intervention Name(s)
    Bupropion HCI ER Tablets, 150 mg; EON Labs Inc.
    Intervention Type
    Drug
    Intervention Name(s)
    WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline
    Primary Outcome Measure Information:
    Title
    Bioequivalence according to US FDA timelines
    Time Frame
    29 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: Positive test results for HIV or hepatitis B or C. Treatment for drug or alcohol dependence.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Shirley A Kennedy, M.D.
    Organizational Affiliation
    Novum Pharmaceutical Research Services
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    A Relative Bioavailability Study of Bupropion HCI 150 mg Sustained-Release Tablets Under Fasting Conditions

    We'll reach out to this number within 24 hrs